As of June 17, 2025, Aequus Pharmaceuticals Inc (AQS.V) reports a ROE (Return on Equity) of 33.74%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Aequus Pharmaceuticals Inc's ROE (Return on Equity)
Over recent years, Aequus Pharmaceuticals Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 33.74% |
| 2023-12-31 | 69.05% |
| 2022-12-31 | 232.60% |
| 2021-12-31 | -101.15% |
| 2020-12-31 | -182.13% |
This slight upward trend highlights how Aequus Pharmaceuticals Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Aequus Pharmaceuticals Inc's ROE (Return on Equity) to Peers
To better understand Aequus Pharmaceuticals Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Aequus Pharmaceuticals Inc (AQS.V) | 33.74% |
| Canada House Cannabis Group Inc (CHV.CN) | 295.58% |
| Sproutly Canada Inc (SPR.CN) | 292.36% |
| American Green Inc (ERBB) | 170.00% |
| Maven Brands Inc (MJ.CN) | 162.17% |
| Exmceuticals Inc (EXM.CN) | 134.41% |
Compared to its competitors, Aequus Pharmaceuticals Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.